Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: an analysis of the PROGRESS and ADVANCE trials

Grants

Funding Acknowledgements

M.W. reports personal fees from Amgen outside the submitted work. P.H. reports consulting fees from Servier. S.H. reports lecture fees from Servier, Takeda, and Novartis. G.M. reports lecture fees from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Medtronic, Novartis, Menarini International, Recordati, Servier, and Takeda. M.M. reports grants and personal fees from Novo Nordisk, grants and personal fees from Sanofi, grants and personal fees from Eli Lilly, personal fees from Servier, grants and personal fees from Merck Sharp & Dohme, personal fees from Abbott, grants and personal fees from Novartis, and personal fees from AstraZeneca outside the submitted work. V.P. reports fees for serving on steering committees from AbbVie, Boehringer Ingelheim, Janssen, Vitae, and Astellas, fees for serving on advisory boards from Eli Lilly, lecture fees from AstraZeneca, Roche, and Merck, and grant support from Baxter, Janssen, and Novartis. N.P. reports honoraria from Servier, Takeda, Menarini, and Pfizer and grant support from Servier and Pfizer. B.W. reports lecture fees from Novartis, Boehringer Ingelheim, and Merck Sharp and Dohme. J.C. reports grants and personal fees from Servier outside the submitted work. George Health Enterprises, the social enterprise arm of the George Institute, has received investment to develop fixed dose combinations of aspirin, statin and blood pressure lowering drugs. No other potential conflict of interest relevant to this article was reported.